全文获取类型
| 收费全文 | 56815篇 |
| 免费 | 3703篇 |
| 国内免费 | 204篇 |
专业分类
| 耳鼻咽喉 | 542篇 |
| 儿科学 | 1709篇 |
| 妇产科学 | 1426篇 |
| 基础医学 | 8209篇 |
| 口腔科学 | 1136篇 |
| 临床医学 | 7966篇 |
| 内科学 | 11087篇 |
| 皮肤病学 | 1127篇 |
| 神经病学 | 5898篇 |
| 特种医学 | 1231篇 |
| 外科学 | 4892篇 |
| 综合类 | 510篇 |
| 一般理论 | 67篇 |
| 预防医学 | 6302篇 |
| 眼科学 | 882篇 |
| 药学 | 3430篇 |
| 中国医学 | 141篇 |
| 肿瘤学 | 4167篇 |
出版年
| 2023年 | 369篇 |
| 2022年 | 670篇 |
| 2021年 | 1448篇 |
| 2020年 | 916篇 |
| 2019年 | 1421篇 |
| 2018年 | 1574篇 |
| 2017年 | 1143篇 |
| 2016年 | 1274篇 |
| 2015年 | 1567篇 |
| 2014年 | 2038篇 |
| 2013年 | 2865篇 |
| 2012年 | 4393篇 |
| 2011年 | 4653篇 |
| 2010年 | 2521篇 |
| 2009年 | 2180篇 |
| 2008年 | 3992篇 |
| 2007年 | 4000篇 |
| 2006年 | 3933篇 |
| 2005年 | 3674篇 |
| 2004年 | 3494篇 |
| 2003年 | 3253篇 |
| 2002年 | 2957篇 |
| 2001年 | 332篇 |
| 2000年 | 224篇 |
| 1999年 | 414篇 |
| 1998年 | 592篇 |
| 1997年 | 518篇 |
| 1996年 | 437篇 |
| 1995年 | 363篇 |
| 1994年 | 338篇 |
| 1993年 | 298篇 |
| 1992年 | 198篇 |
| 1991年 | 158篇 |
| 1990年 | 165篇 |
| 1989年 | 149篇 |
| 1988年 | 121篇 |
| 1987年 | 130篇 |
| 1986年 | 97篇 |
| 1985年 | 118篇 |
| 1984年 | 167篇 |
| 1983年 | 171篇 |
| 1982年 | 205篇 |
| 1981年 | 176篇 |
| 1980年 | 174篇 |
| 1979年 | 102篇 |
| 1978年 | 81篇 |
| 1977年 | 89篇 |
| 1976年 | 62篇 |
| 1975年 | 59篇 |
| 1974年 | 71篇 |
排序方式： 共有10000条查询结果，搜索用时 650 毫秒
1.
Streibert Fridolin Bernhardt Claudia Simon Philipp Hilbert-Carius Peter Wrigge Hermann 《Der Anaesthesist》2023,72(1):57-62
Die Anaesthesiologie - Die Anlage einer Magensonde im OP oder auf einer Intensivstation (ITS) stellt eine alltäglich durchgeführte Prozedur dar. Obwohl die Sonde häufig durch... 相似文献
2.
3.
Emeline Colomba Patricia Pautier Fanny Pommeret Alexandra Leary 《Expert review of anticancer therapy》2019,19(6):437-446
Introduction: The landscape of poly (ADP-ribose) polymerase (PARP) inhibition in ovarian cancer is rapidly evolving and becoming increasingly complex. Ovarian cancer is leading therapeutic innovation by providing the proof of concept for DNA repair as a target. Three different PARP inhibitors have now received approvals in the US and Europe in different indications. Subtle but crucial differences can be found among the licensed indications for each PARP inhibitor in terms of histology, type of BRCA mutation (germline and/or somatic), number of prior lines of chemotherapy and whether the indication is in the treatment or maintenance settings.
Areas covered: We review the latest clinical data regarding the PARP inhibitor rucaparib in ovarian cancer, provide an update on the evolving landscape of PARP inhibition in ovarian cancer, and summarize avenues of ongoing and future research.
Expert opinion: All eligible patients should be offered a PARP inhibitor. SOLO1 trial results demonstrated an unprecedented benefit maintenance with PARP inhibitors in first line. Results from trials evaluating PARP inhibitors as maintenance in first line regardless of BRCA status and from trials evaluating combinatorial strategies are eagerly awaited. 相似文献
4.
5.
6.
7.
Nurse perceptions of the Nursing Delirium Screening Scale in two palliative care inpatient units: a focus group study 
下载免费PDF全文
下载免费PDF全文 8.
Alessia Scarselli Silvia Di Cesare Claudia Capponi Simona Cascioli Maria L. Romiti Gigliola Di Matteo Alessandra Simonetti Paolo Palma Andrea Finocchi Barbarella Lucarelli Rita M. Pinto Ippolita Rana Giuseppe Palumbo Maurizio Caniglia Paolo Rossi Rita Carsetti Caterina Cancrini Alessandro Aiuti 《Journal of clinical immunology》2015,35(4):373-383
9.
Paola Gilsanz Maria M. Corrada Claudia H. Kawas Elizabeth Rose Mayeda M. Maria Glymour Charles P. Quesenberry Catherine Lee Rachel A. Whitmer 《Alzheimer's & dementia》2019,15(4):497-505
Introduction
Little is known about dementia incidence in diverse populations of oldest-old, the age group with highest dementia incidence.Methods
Incident dementia diagnoses from 1/1/2010 to 9/30/2015 were abstracted from medical records for 2350 members of an integrated health care system in California (n = 1702 whites, n = 375 blacks, n = 105 Latinos, n = 168 Asians) aged ≥90 in 2010. We estimated race/ethnicity-specific age-adjusted dementia incidence rates and implemented Cox proportional hazards models and Fine and Gray competing risk of death models adjusted for demographics and comorbidities in midlife and late-life.Results
Dementia incidence rates (n = 771 cases) were lowest among Asians (89.9/1000 person-years), followed by whites (96.9/1000 person-years), Latinos (105.8/1000 person-years), and blacks (121.5/1000 person-years). Cox regression and competing risk models estimated 28% and 36% higher dementia risk for blacks versus whites adjusting for demographics and comorbidities.Discussion
Patterns of racial/ethnic disparities in dementia seen in younger older adults continue after the age of 90 years, though smaller in magnitude. 相似文献10.